FDA Approves First Drug for Treatment of Parkinson’s Dyskinesia

The US Food and Drug Administration (FDA) has approved amantadine extended-release capsules (Gocovri, Adamas Pharmaceuticals Inc) for treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, the [...]

Categories: News|

FDA Approves First Drug for cGVHD After Stem Cell Transplant

In a first, the US Food and Drug Administration (FDA) has approved a drug for use in  patients who develop the life-threatening condition of chronic graft-vs-host disease (cGVHD) after having undergone a hematopoietic stem cell [...]

Categories: News|

Artificial Sweeteners Linked to Higher BMI, Cardiometabolic Risk

A new meta-analysis and systematic review finds mixed evidence to support use of artificial sweeteners for weight loss and suggests routine consumption may be associated with long-term weight gain and an increased risk of cardiometabolic [...]

Categories: News|

FDA Approves Deflazocort (Emflaza®) To Treat Duchenne Muscular Dystrophy (DMD)

On February 9th, 2017 the U.S. Food and Drug Administration (FDA) approved Emflaza® (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (DMD), a rare genetic disorder [...]

Categories: Blog, News, Pharmacy|

Pioglitazone Helps Prevent Secondary Stroke In Patients With Insulin Resistance

Data from a new systematic review and meta-analysis provides evidence the pioglitazone can help prevent secondary stroke in people with abnormal glucose metabolism. Pioglitazone reduced major vascular events after ischemic stroke in a recent randomized [...]

Categories: Blog, News|

FDA approves Darzalex® for patients with previously treated multiple myeloma

On November 16th, 2016 the U.S. Food and Drug Administration (FDA) granted accelerated approval for Darzalex® (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex® is the first [...]

Categories: Blog, News|